California Public Employees Retirement System Has $7.05 Million Stake in Catalent Inc (CTLT)
California Public Employees Retirement System raised its stake in Catalent Inc (NASDAQ:CTLT) by 2.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 200,800 shares of the company’s stock after purchasing an additional 4,400 shares during the quarter. California Public Employees Retirement System owned 0.16% of Catalent worth $7,048,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Catalent by 31.0% in the first quarter. Russell Investments Group Ltd. now owns 20,891 shares of the company’s stock valued at $591,000 after acquiring an additional 4,943 shares in the last quarter. Karp Capital Management Corp bought a new position in shares of Catalent in the first quarter valued at approximately $648,000. Parametric Portfolio Associates LLC grew its holdings in shares of Catalent by 12.3% in the first quarter. Parametric Portfolio Associates LLC now owns 153,781 shares of the company’s stock valued at $4,355,000 after acquiring an additional 16,856 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Catalent by 14.3% in the first quarter. Stifel Financial Corp now owns 10,598 shares of the company’s stock valued at $300,000 after acquiring an additional 1,329 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Catalent by 90.0% in the first quarter. SG Americas Securities LLC now owns 25,097 shares of the company’s stock valued at $711,000 after acquiring an additional 11,886 shares in the last quarter.
Several research firms have recently issued reports on CTLT. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Morgan Stanley raised Catalent from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $29.00 to $48.00 in a report on Thursday, September 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $45.00 target price (up from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Finally, Wells Fargo & Company upped their target price on Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $38.64.
Catalent Inc (CTLT) opened at 42.26 on Friday. The firm’s 50-day moving average price is $40.31 and its 200 day moving average price is $35.18. Catalent Inc has a one year low of $21.83 and a one year high of $42.96. The company has a market capitalization of $5.29 billion and a price-to-earnings ratio of 48.57.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.08. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. During the same quarter in the previous year, the firm posted $0.52 EPS. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, equities research analysts expect that Catalent Inc will post $1.62 earnings per share for the current fiscal year.
In other news, SVP Christine Dolan sold 745 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.